





apolipoprotein E-deficient mice. *Cardiovasc Res.* 2008; 80:191-199.

13. Mattagajasingh I, Kim CS, Naqvi A, Yamamori T, Hoffman TA, Jung SB, DeRicco J, Kasuno K and Irani K. SIRT1 promotes endothelium-dependent vascular relaxation by activating endothelial nitric oxide synthase. *Proc Natl Acad Sci U S A.* 2007; 104:14855-14860.


SUPPLEMENTAL DATA

Supplemental Table 1. Primers used for generation of luciferase reporter constructs with various sizes of the *SIRT1* promoter and mutagenesis


| Amplicon | Primer sequence |
|---|--|
| <i>SIRT1</i> promoter cloning | |
| 1596bp Forward | 5'-CATCACCGCGTGTCTTAACCAGTGGTAGACCAGAA-3' |
| 1083bp Forward | 5'-TTCAGGGAGA GAGGAAAGTG GAAG-3' |
| 773bp Forward | 5'-TTTGAAGCCA AGCTGGGGCC AGAA-3' |
| 553bp Forward | 5'-GGAGCCGCCT CCTTTGCCT CTCT-3' |
| 377bp Forward | 5'-CATCACCGCGTCGGACAAAATTGAGCTGT |
| 299bp Forward | 5'-CATCACCGCGTCGAATTGGCTGCACTACAC |
| 211bp Forward | 5'-CATCACCGCGTAGACGCAACAGCCTCCGCC |
| 164bp Forward | 5'-CATCACCGCGTGGCCCGCGTGGTGGCGGG |
| All sizes' Reverse | 5'-CATGCTCGAGCTTCCAATGCCTCTGGC |
| <i>FOXO3</i> site directed mutagenesis | |
| Site1 Forward | 5'-CTCTCCTACTTATTAACGGGACAGAACGACTATCCAACGTATTCAGGG-3' |
| Site1 Reverse | 5'-CCCTGAAATACGTTGGATAGTCGTTCTGTCCCCTTAATAAGTAGGAAGAG-3' |
| Site2 Forward | 5'-TAGCCAGCTTCAGCTGTGCCCTAACCTTAGCTAAATATAGACAAGGCTA-3' |
| Site2 Reverse | 5'-TAGCCTTGTCTATTTAGGCTAAGGGTTAGGGCACAGCTGAAGCTGGCTA-3' |

A**B****C****D**

Supplemental Figure 1. Measurement of SIRT1 levels for identification of *SIRT1* gene activator. (A) SIRT1 mRNA levels measured by qRT-PCR after treating HUVECs with the extracts from 12 herbs. (B) SIRT1 mRNA levels in various part of *Panax ginseng* were measured by qRT-PCR and compared to control (non-treated). (C) Purification steps to isolate a bio-active compound, from *Panax ginseng* berry (GB) extracts. Fractions that induced SIRT1 mRNA levels in HUVECs are indicated in circles. GB-3731-1 was found to be syringaresinol. See Methods for detailed information. (D) Cytotoxicity of syringaresinol was tested by treating HUVECs with the indicated concentration of syringaresinol for 24 h. Data are mean \pm S.E. of triplicate determinations.



Supplemental Figure 2. IL-6 and IL-8 produced by cells with indicated treatment were determined by ELISA and the relative levels to PDL14 were compared. The results are mean \pm S.E of four independent experiments and significance was assessed by *t*-test. ***P < 0.005.



Supplemental Figure 3. Quantification of the protein levels shown in the Fig 4. The results are means \pm S.E of three independent experiments. Significance was assessed by *t*-test. *P < 0.05, **P < 0.01.